Literature DB >> 33885175

Assessment of clinical factors affecting outcome of myasthenia gravis.

Yukiyo Yoshimoto1, Shimon Ishida1, Takafumi Hosokawa1, Shigeki Arawaka1.   

Abstract

INTRODUCTION/AIMS: In myasthenia gravis (MG) therapy, achieving Myasthenia Gravis Foundation of America minimal manifestation (MM) or better status is proposed as a desirable target. However, this level of control is often not achieved and clinical factors affecting prognosis remain unclear.
METHODS: Participants were 104 consecutive patients with MG who visited Osaka Medical College Hospital. We retrospectively assessed the association of clinical and laboratory features at baseline with prognosis. Eighty patients who achieved MM or better status were classified as the good outcome group and the remaining 24 patients were classified as the poor outcome group.
RESULTS: The rate of dysphagia at baseline was significantly higher in the poor outcome group than in the good outcome group (P = .002). The levels of serum total protein and albumin at baseline were both significantly lower in the poor outcome group than in the good outcome group (P = .036 and P = .014, respectively). In addition, Controlling Nutritional Status scores at baseline were significantly higher in the poor outcome group than in the good outcome group (P = .043). Multivariate analysis using a Cox proportional hazards model showed that dysphagia (hazard ratio [HR], 6.92; 95% confidence interval [CI], 1.49-40.31) and hypoalbuminemia (HR, 2.57; 95% CI, 1.04-6.57) at baseline were risk factors that predicted prognosis. DISCUSSION: These findings suggest that dysphagia and hypoalbuminemia at baseline are associated with outcomes and are predictive risk factors for poorer outcomes in patients with MG.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CONUT score; dysphagia; hypoalbuminemia; myasthenia gravis; prognosis

Year:  2021        PMID: 33885175     DOI: 10.1002/mus.27247

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  1 in total

Review 1.  Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders.

Authors:  E Sally Ward; Deborah Gelinas; Erwin Dreesen; Jolien Van Santbergen; Jan Terje Andersen; Nicholas J Silvestri; Joseph E Kiss; Darrell Sleep; Daniel J Rader; John J P Kastelein; Els Louagie; Gestur Vidarsson; Isabel Spriet
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.